The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Open accessAbstract
The priming of an appropriate anti‐tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell‐mediated rejection are unknown for many tumors. We report on evidence that the expression of the immunosuppressive enzyme, indoleamine 2,3‐dioxygenase (IDO) by mononuclear cells that invade tumors and tumor‐draining lymph nodes, is 1 mechanism that may account for this observation. Lewis lung carcinoma (LLC) cells stimulated a more robust allogeneic T cell response in vitro in the presence of a competitive inhibitor of IDO, 1‐methyl tryptophan. When administered in vivo this inhibitor also resulted in delayed LLC tumor growth in syngeneic mice. Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti‐cancer immunotherapeutic strategy. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Self-citationInhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
Self-citationRelationship between interferon‐γ, indoleamine 2,3‐dioxygenase, and tryptophan catabolism
Taylor, M. W., & Feng, G. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.11.1907934 · Cited by 1,060
Hwu, P., Du, M. X., Lapointe, R., Do, M., Taylor, M. W., & Young, H. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3596 · Cited by 739
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 648
Self-citationAlterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice
Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., & Ochoa, A. C. (1992) · Science · doi:10.1126/science.1465616 · Cited by 632
Romero, P., Rod Dunbar, P., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J.-L., Liénard, D., Cerottini, J.-C., & Cerundolo, V. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1641 · Cited by 521
Schönrich, G., Kalinke, U., Momburg, F., Malissen, M., Schmitt-Verhulst, A.-M., Malissen, B., Hämmerling, G. J., & Arnold, B. (1991) · Cell · doi:10.1016/0092-8674(91)90163-s · Cited by 506
Immune surveillance against a solid tumor fails because of immunological ignorance
Ochsenbein, A. F., Klenerman, P., Karrer, U., Ludewig, B., Pericin, M., Hengartner, H., & Zinkernagel, R. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2233 · Cited by 453
Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F.-M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., & Levitsky, H. I. (1999) · Nature Medicine · doi:10.1038/10503 · Cited by 407
The host—tumor immune conflict: from immunosuppression to resistance and destruction
Chouaib, S., Asselin-Paturel, C., Mami-Chouaib, F., Caignard, A., & Blay, J. Y. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01115-8 · Cited by 350
Speiser, D. E., Miranda, R., Zakarian, A., Bachmann, M. F., McKall-Faienza, K., Odermatt, B., Hanahan, D., Zinkernagel, R. M., & Ohashi, P. S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.5.645 · Cited by 309
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape
Restifo, N. P. (2000) · Nature Medicine · doi:10.1038/74955 · Cited by 251
Induction of indoleamine 2,3-dioxygenase: a mechanism of the antitumor activity of interferon gamma.
Ozaki, Y., Edelstein, M. P., & Duch, D. S. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1242 · Cited by 240
Establishment of a cloned line of Lewis lung carcinoma cells adapted to cell culture
Bertram, J. S., & Janik, P. (1980) · Cancer Letters · doi:10.1016/0304-3835(80)90130-5 · Cited by 216
Wick, M., Dubey, P., Koeppen, H., Siegel, C. T., Fields, P. E., Chen, L., Bluestone, J. A., & Schreiber, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.229 · Cited by 195
Anichini, A., Molla, A., Mortarini, R., Tragni, G., Bersani, I., Di Nicola, M., Gianni, A. M., Pilotti, S., Dunbar, R., Cerundolo, V., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.651 · Cited by 190
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Chappell, D. B., Zaks, T. Z., Rosenberg, S. A., & Restifo, N. P. (1999) · PubMed · Cited by 133
Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
Ganss, R., & Hanahan, D. (1998) · PubMed · Cited by 121
Yu, W., Yamamoto, N., Takenaka, H., Mu, J., Tai, X., Zou, J.-P., Ogowa, M., Tsutsui, T., Wijesuriya, R., Yoshida, R., et al. (1996) · International Immunology · doi:10.1093/intimm/8.6.855 · Cited by 89
Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo
Radoja, S., Rao, T. D., Hillman, D., & Frey, A. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2619 · Cited by 88
Tryptophan degradation in transplanted tumor cells undergoing rejection.
Yoshida, R., Park, S. W., Yasui, H., et al. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.8.2819 · Cited by 78
Favre-Félix, N., Fromentin, A., Hammann, A., Solary, É., Martin, F., & Bonnotte, B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5023 · Cited by 77
Takikawa, O., Habara-Ohkubo, A., & Yoshida, R. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.4.1246 · Cited by 70
Hermans, I. F., Daish, A., Yang, J., Ritchie, D., & Ronchese, F. (1998) · PubMed · Cited by 60
Hua, C., Boyer, C., Buferne, M., & Schmitt‐Verhulst, A. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.6.1937 · Cited by 59
Regulation of prostaglandin synthesis and cell adhesion by a tryptophan catabolizing enzyme
Marshall, B., Keskin, D. B., & Mellor, A. L. (2001) · BMC Biochemistry · doi:10.1186/1471-2091-2-5 · Cited by 31
Self-citation
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Self-citationUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.011 · Cited by 865
Metadata
- Authors
- Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2002-07-26
- Volume
- 101
- Issue
- 2
- Pages
- 151-155
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1967404929
- Cited by
- 365
- References
- 29
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.